TET1 and cervical carcinoma: Our data suggest that the PRMT5 inhibitor EPZ015666 can lead to an induction of TET1 expression and 5hmC, and inhibit the invasive potential of cervical cancer cells, making PRMT5 a potential target for cancer diagnosis and treatment.